Last reviewed · How we verify
NCT07251231: Parkinson
Effectiveness of Virtual Reality in Parkinson's Disease: Effects on Balance, Fall Risk, and Exercise Capacity.
NA trial testing Virtual Reality in Parkinson Disease in 50 participants. Not yet recruiting.
1 May 2026
Quick facts
| Lead sponsor | University of Valencia |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 January 2026 |
| Primary completion | 1 May 2026 |
| Estimated completion | 1 January 2027 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Virtual Reality
- Conventional Rehabilitation
Conditions studied
- Parkinson Disease — all drugs for Parkinson Disease →
Sponsor
University of Valencia
Who can join
Adults 55 to 75, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to evaluate whether immersive virtual reality (VR)-based physiotherapy is effective in improving balance, reducing fall risk, and enhancing cardiorespiratory exercise capacity in individuals with Parkinson's disease. The main questions it aims to answer are: Does immersive VR therapy improve postural balance more effectively than conventional physiotherapy? Does immersive VR reduce fall risk and increase cardiorespiratory fitness compared with standard physiotherapy? Researchers will compare an immersive VR intervention with conventional physiotherapy to determine whether VR can produce superior functional and physiological outcomes in patients with Parkinson's disease. Participants will: Be randomly assigned (1:1) to an experimental group (immersive VR therapy) or a control group (conventional physiotherapy). Take part in structured physiotherapy sessions focused on balance, mobility, and functional capacity. Undergo pre- and post-intervention assessments of balance, fall risk, cardiorespiratory exercise capacity, and quality of life. This randomized controlled trial (RCT) with parallel assignment will include 50 participants (25 per group). Randomization will be performed using the OxMaR (Oxford Minimization and Randomization) software, which enables adaptive randomization to ensure balanced baseline characteristics between groups. Secondary objectives include evaluating the impact of immersive VR on health-related quality of life and comparing treatment adherence between VR-based and conventional physiotherapy interventions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07251231
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Virtual Reality
Trials testing the same drug.
- NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
- NCT07512999 — The Effect of Using Nature Sounds and Virtual Reality During the Non-Stress Test · NA · not yet recruiting
- NCT07520253 — Effect of Virtual Reality on Cortical Reorganization and Upper Extremity Functional Recovery in Patients With Subacute S · NA · not yet recruiting
- NCT07462039 — Effect of Virtual Reality on Pain and Anxiety During Pap Smear Testing · NA · not yet recruiting
- NCT07400874 — Use of Acupressure, Aromatherapy, and Virtual Reality for Children in During Blood Collection Procedures · NA · not yet recruiting
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
- NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
- NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
- NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting
Other University of Valencia trials
Trials by the same sponsor.
- NCT07509281 — Peri-implant Tissues Changes for Different Abutment Shapes and Heights · NA · not yet recruiting
- NCT07535528 — Implant Placement Depth and Peri-Implant Tissue Outcomes · NA · not yet recruiting
- NCT07471555 — Vascular Access and Intraosseus · NA · enrolling by invitation
- NCT07463066 — Long-Term Effectiveness of Pain Neuroscience Education in Women With Genito-Pelvic Pain/Penetration Disorder. · not yet recruiting
- NCT07419399 — Acute Effects of Radiofrequency Diathermy in Postpartum Women With Diastasis Abdominis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07251231 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Valencia
- Last refreshed: 4 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07251231.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing